In addition, as Polk-deficient cancer cells are sensitive to different classes of DNA damaging agents, recurrence due to acquired resistance of such cancer cells to one class of cytotoxic drugs could be mitigated by switching to a different class of DNA damaging agents. The gene discussed is POLK; the disease is cancer.